Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Interactions between cannabidiol and commonly used antiepileptic drugs
Tyler E. Gaston, E. Martina Bebin, Gary Cutter, et al.
Epilepsia (2017) Vol. 58, Iss. 9, pp. 1586-1592
Open Access | Times Cited: 312

Showing 1-25 of 312 citing articles:

Cannabinoids and the expanded endocannabinoid system in neurological disorders
Luigia Cristino, Tiziana Bisogno, Vincenzo Di Marzo
Nature Reviews Neurology (2019) Vol. 16, Iss. 1, pp. 9-29
Closed Access | Times Cited: 776
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Sophie Millar, Nicole L. Stone, Andrew Yates, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 425
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
Orrin Devinsky, Anup D. Patel, Elizabeth A. Thiele, et al.
Neurology (2018) Vol. 90, Iss. 14
Open Access | Times Cited: 390
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
Lesley Taylor, Barry E. Gidal, Graham Blakey, et al.
CNS Drugs (2018) Vol. 32, Iss. 11, pp. 1053-1067
Open Access | Times Cited: 370
Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
Orrin Devinsky, Rima Nabbout, Ian Miller, et al.
Epilepsia (2018) Vol. 60, Iss. 2, pp. 294-302
Open Access | Times Cited: 243
Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use
Joshua D. Brown, Almut G. Winterstein
Journal of Clinical Medicine (2019) Vol. 8, Iss. 7, pp. 989-989
Open Access | Times Cited: 238
Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials
Serena Silvestro, Santa Mammana, Eugenio Cavalli, et al.
Molecules (2019) Vol. 24, Iss. 8, pp. 1459-1459
Open Access | Times Cited: 218
Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?
Emilio Perucca
Journal of Epilepsy Research (2017) Vol. 7, Iss. 2, pp. 61-76
Open Access | Times Cited: 208
Clinicians’ Guide to Cannabidiol and Hemp Oils
Harrison VanDolah, Brent A. Bauer, Karen F. Mauck
Mayo Clinic Proceedings (2019) Vol. 94, Iss. 9, pp. 1840-1851
Open Access | Times Cited: 198
A systematic review of cannabidiol dosing in clinical populations
Sophie Millar, Nicole L. Stone, Z.D. Bellman, et al.
British Journal of Clinical Pharmacology (2019) Vol. 85, Iss. 9, pp. 1888-1900
Open Access | Times Cited: 197
Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results
Jerzy P. Szaflarski, E. Martina Bebin, Anne M. Comi, et al.
Epilepsia (2018) Vol. 59, Iss. 8, pp. 1540-1548
Open Access | Times Cited: 185
Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders
Daniel Friedman, Jacqueline A. French, Mauro Maccarrone
The Lancet Neurology (2019) Vol. 18, Iss. 5, pp. 504-512
Closed Access | Times Cited: 185
A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
Gilmour Morrison, Julie C. Crockett, Graham Blakey, et al.
Clinical Pharmacology in Drug Development (2019) Vol. 8, Iss. 8, pp. 1009-1031
Open Access | Times Cited: 175
Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes
Orrin Devinsky, Chloe Verducci, Elizabeth A. Thiele, et al.
Epilepsy & Behavior (2018) Vol. 86, pp. 131-137
Closed Access | Times Cited: 162
Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study
Jerzy P. Szaflarski, Elizabeth M. Bebin, Gary Cutter, et al.
Epilepsy & Behavior (2018) Vol. 87, pp. 131-136
Open Access | Times Cited: 161
Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination
Joana Gonçalves, Tiago Rosado, Sofia Soares, et al.
Medicines (2019) Vol. 6, Iss. 1, pp. 31-31
Open Access | Times Cited: 159
Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy
Valentina Franco, Emilio Perucca
Drugs (2019) Vol. 79, Iss. 13, pp. 1435-1454
Closed Access | Times Cited: 147
Cannabidiol modulates excitatory-inhibitory ratio to counter hippocampal hyperactivity
Evan C. Rosenberg, Simon Chamberland, Michaël Bazelot, et al.
Neuron (2023) Vol. 111, Iss. 8, pp. 1282-1300.e8
Open Access | Times Cited: 51
Medicinal Cannabis—Potential Drug Interactions
Indeewarie Hemamali Dissanayake, Chun Guang Li
Medicines (2018) Vol. 6, Iss. 1, pp. 3-3
Open Access | Times Cited: 149
Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy
Stephanie McGrath, Lisa R. Bartner, Sangeeta Rao, et al.
Journal of the American Veterinary Medical Association (2019) Vol. 254, Iss. 11, pp. 1301-1308
Closed Access | Times Cited: 142
Cannabis for the Treatment of Epilepsy: an Update
Tyler E. Gaston, Jerzy P. Szaflarski
Current Neurology and Neuroscience Reports (2018) Vol. 18, Iss. 11
Closed Access | Times Cited: 135
Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies
Anastasia Suraev, Nathaniel S. Marshall, Ryan G. Vandrey, et al.
Sleep Medicine Reviews (2020) Vol. 53, pp. 101339-101339
Closed Access | Times Cited: 134
Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions
Lyndsey L. Anderson, Nathan L. Absalom, Sarah V. Abelev, et al.
Epilepsia (2019) Vol. 60, Iss. 11, pp. 2224-2234
Open Access | Times Cited: 128
Update on Antiepileptic Drugs 2019
Bassel Abou‐Khalil
CONTINUUM Lifelong Learning in Neurology (2019) Vol. 25, Iss. 2, pp. 508-536
Closed Access | Times Cited: 122
Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells
David M. Elliott, Narendra P. Singh, Prakash Nagarkatti, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 116
Page 1 - Next Page

Scroll to top